Partial Nicotine Reduction and E-Cigarette Users' Puffing Behaviors Among Adults Aged 21 to 35 Years: A Randomized Crossover Clinical Trial.

What Was Tested

Researchers studied Therapeutic nicotine (patch, non-peptide) in this randomized controlled trial publication.

The advent of salt-based, high-nicotine electronic nicotine delivery systems [e-cigarettes] has contributed to their epidemic use among young people in the US, necessitating the need for policies to address the addictiveness of these products.

Who Took Part

PubMed indexes the participants as young adults and adults, both men and women.

In each session, participants vaped up to 60 minutes ad libitum, preceded by 12 hours of nicotine abstinence.

How the Study Was Run

The researchers set it up as a randomized and crossover study.

Because people in this Therapeutic nicotine (patch, non-peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Each person switched between Therapeutic nicotine (patch, non-peptide) and the comparison at some point, usually with a gap in between.

This randomized crossover clinical trial was conducted at the Clinical Research Lab for Tobacco Smoking at Florida International University in Miami between April 15, 2022, and October 17, 2023.

What Was Measured

The subject headings attached to it are Electronic Nicotine Delivery Systems, Nicotine, Vaping and Smoking Cessation.

What This Means in Plain Language

The paper is a randomized and crossover study of Therapeutic nicotine (patch, non-peptide).

The abstract goes on to report its results in about 9 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2024 (JAMA network open), a journal based in United States.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.